172 related articles for article (PubMed ID: 24740294)
1. Relationship between p53 status and response to chemotherapy in patients with gastric cancer: a meta-analysis.
Xu HY; Xu WL; Wang LQ; Chen MB; Shen HL
PLoS One; 2014; 9(4):e95371. PubMed ID: 24740294
[TBL] [Abstract][Full Text] [Related]
2. P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer.
Chen MB; Wu XY; Yu R; Li C; Wang LQ; Shen W; Lu PH
PLoS One; 2012; 7(9):e45388. PubMed ID: 23049793
[TBL] [Abstract][Full Text] [Related]
3. Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
Chen MB; Zhu YQ; Xu JY; Wang LQ; Liu CY; Ji ZY; Lu PH
PLoS One; 2012; 7(6):e39655. PubMed ID: 22768103
[TBL] [Abstract][Full Text] [Related]
4. Allelic imbalance at p53 and microsatellite instability are predictive markers for resistance to chemotherapy in gastric carcinoma.
Yashiro M; Inoue T; Nishioka N; Matsuoka T; Boland CR; Hirakawa K
Ann Surg Oncol; 2009 Oct; 16(10):2926-35. PubMed ID: 19597886
[TBL] [Abstract][Full Text] [Related]
5. Correlation of p53 status with the response to chemotherapy-based treatment in esophageal cancer: a meta-analysis.
Zhang SS; Huang QY; Yang H; Xie X; Luo KJ; Wen J; Cai XL; Yang F; Hu Y; Fu JH
Ann Surg Oncol; 2013 Jul; 20(7):2419-27. PubMed ID: 23515910
[TBL] [Abstract][Full Text] [Related]
6. Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma.
Ott K; Vogelsang H; Mueller J; Becker K; Müller M; Fink U; Siewert JR; Höfler H; Keller G
Clin Cancer Res; 2003 Jun; 9(6):2307-15. PubMed ID: 12796400
[TBL] [Abstract][Full Text] [Related]
7. Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer.
Bataille F; Rümmele P; Dietmaier W; Gaag D; Klebl F; Reichle A; Wild P; Hofstädter F; Hartmann A
Mol Pathol; 2003 Oct; 56(5):286-92. PubMed ID: 14514923
[TBL] [Abstract][Full Text] [Related]
8. Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer.
Pallocca M; Goeman F; De Nicola F; Melucci E; Sperati F; Terrenato I; Pizzuti L; Casini B; Gallo E; Amoreo CA; Vici P; Di Lauro L; Buglioni S; Diodoro MG; Pescarmona E; Mazzotta M; Barba M; Fanciulli M; De Maria R; Ciliberto G; Maugeri-Saccà M
J Transl Med; 2018 Sep; 16(1):247. PubMed ID: 30180862
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of tumor regression grade following the administration of neoadjuvant chemotherapy as treatment for gastric/gastroesophageal adenocarcinoma: A meta-analysis of 14 published studies.
Hayashi M; Fujita T; Matsushita H
Eur J Surg Oncol; 2021 Aug; 47(8):1996-2003. PubMed ID: 33353828
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study of the predictors to neoadjuvant chemotherapy in patients with advanced gastric cancer].
Qu JJ; Shi YR; Hao FY
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):276-80. PubMed ID: 23536352
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: a meta-analysis.
Ge L; Wang HJ; Yin D; Lei C; Zhu JF; Cai XH; Zhang GQ
World J Gastroenterol; 2012 Dec; 18(48):7384-93. PubMed ID: 23326149
[TBL] [Abstract][Full Text] [Related]
12. [Effects of XELOX regimen as neoadjuvant chemotherapy on radical resection rate and prognosis in patients with advanced gastric cancer].
Zhao Q; Li Y; Tan BB; Tian Y; Jiao ZK; Zhao XF; Zhang ZD; Wang D; Yang PG
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):773-7. PubMed ID: 24378101
[TBL] [Abstract][Full Text] [Related]
13. The predictors of response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer.
Qu J; Qu X
Cancer Biomark; 2016 Jun; 17(1):49-54. PubMed ID: 27314292
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials.
Zhao X; Ren Y; Hu Y; Cui N; Wang X; Cui Y
PLoS One; 2018; 13(8):e0202185. PubMed ID: 30138325
[TBL] [Abstract][Full Text] [Related]
15. rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy.
Chen GX; Zheng LH; Liu SY; He XH
World J Gastroenterol; 2011 Oct; 17(38):4289-97. PubMed ID: 22090785
[TBL] [Abstract][Full Text] [Related]
16. X-ray repair cross-complementing 1 polymorphism and prognosis of platinum-based chemotherapy in gastric and colorectal cancer: a meta-analysis.
Wu H; Xu C; Chen G; Wang J
J Gastroenterol Hepatol; 2014 May; 29(5):926-33. PubMed ID: 24224851
[TBL] [Abstract][Full Text] [Related]
17. A compensatory role of NF-κB to p53 in response to 5-FU-based chemotherapy for gastric cancer cell lines.
Endo F; Nishizuka SS; Kume K; Ishida K; Katagiri H; Ishida K; Sato K; Iwaya T; Koeda K; Wakabayashi G
PLoS One; 2014; 9(2):e90155. PubMed ID: 24587255
[TBL] [Abstract][Full Text] [Related]
18. Relationship between the long-term effects of intraperitoneal chemotherapy and the expression of p53 and p21 in patients with gastric carcinoma at stage IIIa and stage IIIb.
Ikeguchi M; Saito H; Katano K; Gomyo Y; Tsujitani S; Maeta M; Kaibara N
Int Surg; 1997; 82(2):170-4. PubMed ID: 9331847
[TBL] [Abstract][Full Text] [Related]
19. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents.
Nabeya Y; Loganzo F; Maslak P; Lai L; de Oliveira AR; Schwartz GK; Blundell ML; Altorki NK; Kelsen DP; Albino AP
Int J Cancer; 1995 Feb; 64(1):37-46. PubMed ID: 7665247
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: a systematic review and meta-analysis.
Yang D; Chen MB; Wang LQ; Yang L; Liu CY; Lu PH
J Exp Clin Cancer Res; 2013 Dec; 32(1):105. PubMed ID: 24370277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
